DRUG vs. CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, GYRE, VIR, and DNA
Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), Gyre Therapeutics (GYRE), Vir Biotechnology (VIR), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.
Bright Minds Biosciences vs. Its Competitors
Bright Minds Biosciences (NASDAQ:DRUG) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Bright Minds Biosciences has a net margin of 0.00% compared to Avid Bioservices' net margin of -101.07%. Bright Minds Biosciences' return on equity of -14.56% beat Avid Bioservices' return on equity.
Bright Minds Biosciences has a beta of -6.01, meaning that its share price is 701% less volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 3.1% of Avid Bioservices shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Bright Minds Biosciences has higher earnings, but lower revenue than Avid Bioservices. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Avid Bioservices, indicating that it is currently the more affordable of the two stocks.
Bright Minds Biosciences currently has a consensus target price of $83.25, indicating a potential upside of 221.06%. Avid Bioservices has a consensus target price of $12.25, indicating a potential downside of 1.96%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Bright Minds Biosciences is more favorable than Avid Bioservices.
In the previous week, Bright Minds Biosciences had 5 more articles in the media than Avid Bioservices. MarketBeat recorded 6 mentions for Bright Minds Biosciences and 1 mentions for Avid Bioservices. Avid Bioservices' average media sentiment score of 0.00 beat Bright Minds Biosciences' score of -0.22 indicating that Avid Bioservices is being referred to more favorably in the news media.
Summary
Bright Minds Biosciences beats Avid Bioservices on 10 of the 16 factors compared between the two stocks.
Get Bright Minds Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bright Minds Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:DRUG) was last updated on 7/11/2025 by MarketBeat.com Staff
Free DRUG Stock Alerts